What does the evidence say about Pterostilbene Cognition Randomized Trial?

The current Migaku evidence database contains 1 reusable source document for Pterostilbene Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Mimio improved more over time in all hunger and satiety metrics than placebo (Hunger and Satiety Composite Score Mann-Kendall p = 2.2*10− 16). [Grant AD (2026); evidence level 4] - More participants in the Mimio group improved daily ratings of hunger and appetite compared to placebo, including 91% vs. [Grant AD (2026); evidence level 4] - Mimio significantly reduced total cholesterol, LDL cholesterol, LDL particle number, oxidized LDL, non-HDL cholesterol and fasting glucose compared to placebo (Student’s t-test p < 0.05). [Grant AD (2026); evidence level 4] - This decentralized, double-blind, randomized, placebo-controlled trial investigated the impact of a novel fasting mimetic “Mimio” on hunger, satiety, digestive symptoms, metabolism, cognition and wellbeing in overweight older adults with elevated HbA1c. [Grant AD (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.